Epigenetic therapies for non-oncology indications

Chronic and degenerative disorders are a major, and growing, human health burden, and current treatments are in many cases inadequate or very expensive. Epigenetic therapies are attractive options for treating such disorders because they manipulate the processes that maintain cells in an abnormal tr...

Full description

Saved in:
Bibliographic Details
Published inDrug discovery today Vol. 15; no. 23; pp. 1008 - 1014
Main Authors Best, Jonathan D., Carey, Nessa
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.2010
Subjects
Autoimmune diseases
Autoimmune Diseases - genetics
Autoimmune Diseases - therapy
Central Nervous System Diseases - genetics
Central Nervous System Diseases - therapy
Diabetes Complications - genetics
Diabetes Complications - therapy
Epigenomics
Humans
Online AccessGet full text

Cover

More Information
Summary:Chronic and degenerative disorders are a major, and growing, human health burden, and current treatments are in many cases inadequate or very expensive. Epigenetic therapies are attractive options for treating such disorders because they manipulate the processes that maintain cells in an abnormal transcriptional state. The challenges lie in identifying the most appropriate diseases and the enzymes that should be targeted. This review describes the different approaches that can be used to address this problem, focusing particularly on CNS disorders (especially mental retardation, neurodegenerative disease, psychiatric disorders and drug addiction), diabetes and diabetic complications, and autoimmunity and inflammatory diseases.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2010.10.006